Abstract
It is well known that cases with multiple myeloma reveal various clinical manifestations such as pancytopenia, hyperproteinemia, renal dysfunction, bone lesions, hypercalcemia and immunodeficiency. Recently, a few more clinical features associated with myeloma, such as salivary type hyperamylasemia and elevated serum C-reactive protein (CRP) concentration, have been reported. The elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells. More recently, there have been several reports of cases with myeloma associated with hyperammonemia. This hyperammonemia is not considered to be due to liver dysfunction, because in most of these cases tests revealed normal hepatic function, and some cases showed different patterns of serum amino acid distribution than that associated with hepatic failure. However, there have been no apparent observations of ammonia production by myeloma cells. In this study, we used six human myeloma cell lines including KMS-18, which was recently established from a myeloma case associated with hyperammonemia. These lines were treated with MRA (mycoplasma removal agent) to observe ammonia production in vitro. They produced and released significantly higher levels of ammonia into culture medium than non-myeloma hematological cell lines or the HepG2 human hepatic carcinoma cell line. Although attempts to analyze the relative expression levels of the enzymes related to ammonia biosynthesis using the reverse transcriptase-polymerase chain reaction assay failed to detect any differences between these myeloma lines and other cell lines, in vitro excess ammonia production by the myeloma cells was confirmed and the relevance to clinical manifestations is discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Otsuki, T., Yamada, O., Sakaguchi, H. et al. In vitro excess ammonia production in human myeloma cell lines. Leukemia 12, 1149–1158 (1998). https://doi.org/10.1038/sj.leu.2401077
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401077
Keywords
This article is cited by
-
Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report
Diagnostic Pathology (2023)
-
Hyperammonemia and lactic acidosis in adults: Differential diagnoses with a focus on inborn errors of metabolism
Reviews in Endocrine and Metabolic Disorders (2018)
-
Non-cirrhotic Hyperammonemia—When High Ammonia Is not Always from Cirrhosis
Current Hepatology Reports (2015)
-
Hyperammonemia, resolved by chemotherapy
Annals of Hematology (2014)
-
Hyperammonemic encephalopathy in multiple myeloma
Annals of Hematology (2014)